Tag: Chemotherapy induced neutropenia

Recent advancements are revolutionizing the treatment of neutropenia, moving beyond the long-standing use of injectable therapies toward more targeted and convenient options. The most significant recent news in this space is the FDA approval of mavorixafor, an oral medication, offering a novel approach for a specific rare form of the condition. If you've been asking 'What is the new drug for neutropenia?', the answer involves several key developments.

Neutropenia, a low neutrophil count, is a common and serious complication of chemotherapy, affecting up to 50% of patients receiving treatment. For many individuals, especially those at high risk of infection, Granulocyte-Colony Stimulating Factors (G-CSFs) are considered the primary **drug of choice for neutropenia** to stimulate white blood cell production and mitigate infectious risks.